Delving into the Latest Updates on KITE-197 with Synapse

Overview

Basic Info

Drug Type

Autologous CAR-T

Synonyms

KITE 197, KITE197

Target

CD19

Action

inhibitors

Mechanism

CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication

Large B-cell lymphoma

Inactive Indication-

Originator Organization

Kite Pharma, Inc.

Active Organization

Kite Pharma, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in participants with relapsed or refractory large B-cell lymphoma (r/rLBCL). The goal of Phase 1b of this clinical study is learn about the effectiveness of the recommended dose of KITE-197 in participants with r/r LBCL.
The primary objectives of this study are:
Phase 1a: To evaluate the safety of KITE-197 in participants with r/r LBCL and determine the target dose level for Phase 1b.
Phase 1b: To evaluate the efficacy of KITE-197 in participants with r/r LBCL as measured by the complete remission (CR) rate.

Start Date09 Nov 2023

Sponsor / Collaborator

Kite Pharma, Inc.

NCT05041309

/ Enrolling by invitationNot Applicable

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, and anitocabtagene autoleucel in participants of Kite-sponsored interventional studies.

Start Date15 Dec 2021

Sponsor / Collaborator

Kite Pharma, Inc.

100 Clinical Results associated with KITE-197

Login to view more data

100 Translational Medicine associated with KITE-197

Login to view more data

100 Patents (Medical) associated with KITE-197

Login to view more data

100 Deals associated with KITE-197

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Large B-cell lymphoma	Phase 1	United States	Kite Pharma, Inc.	09 Nov 2023
Large B-cell lymphoma	Phase 1	Australia	Kite Pharma, Inc.	09 Nov 2023
Large B-cell lymphoma	Phase 1	Canada	Kite Pharma, Inc.	09 Nov 2023